Warner Chilcott Announces Approval of DORYX Delayed-Release 150 Mg Tablets
Posted on: Tuesday, 24 June 2008, 02:29 CDT
ST. DAVID'S, Bermuda, June 23, 2008 (PRIME NEWSWIRE) -- Warner Chilcott Limited (Nasdaq:WCRX) announced today that the Food and Drug Administration (FDA) has approved a 150 mg strength of DORYX(r) (doxycycline hyclate) Delayed-Release Tablets.
DORYX Delayed-Release Tablets are a tetracycline-class oral antibiotic indicated for adjunctive treatment of severe acne. DORYX Delayed-Release Tablets contain enteric-coated pellets of doxycycline hyclate which do not release until they reach the small intestine, thereby minimizing the gastrointestinal side effects most commonly associated with other doxycycline products. The introduction of the 150 mg tablet strength to the existing DORYX Delayed-Release Tablets franchise of 100 mg and 75 mg offers greater dosing flexibility.
The Company will continue to offer DORYX in 75 mg and 100 mg strengths.
Important Safety Information about DORYX(r) Delayed-Release Tablets
Doxycycline, like other tetracycline-class antibiotics, can cause fetal harm when administered to a pregnant woman. Tetracycline-class antibiotics used during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years) may cause permanent discoloration of teeth and should not be used unless other drugs are not likely to be effective or are contraindicated.
Patients should be advised that photosensitivity can occur with tetracycline-class drugs. Clostridium difficile associated diarrhea (CDAD) has been reported with nearly all antibacterial agents and may range from mild diarrhea to fatal colitis. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, DORYX(r) should be used only as indicated. Oral antibiotics may lessen the effectiveness of birth control pills.
For Full Prescribing Information, please visit www.doryx.com.
The Company
Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare and dermatology segments of the U.S. pharmaceuticals market. The Company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. WCRX-G
This news release was distributed by PrimeNewswire, www.primenewswire.com
CONTACT: Warner Chilcott Limited Investor Relations Rochelle Fuhrmann 973-442-3281 rfuhrmann@wcrx.com
Source: PrimeNewswire
Related Articles
- SETDA Releases the Final Report in Class of 2020: Action Plan for Education Series -- "Learning Virtually: Expanding Opportunities"
- Ambien CR(R) (Zolpidem Tartrate Extended-Release) CIV Tablets Improved Insomnia and Daily Functioning in Patients With Co-Morbid Major Depressive Disorder
- UPDATE: FDA Approves ISENTRESS(TM) (Raltegravir) Tablets, First-in-Class Oral HIV-1 Integrase Inhibitor
- FDA Approves ISENTRESS(TM) (Raltegravir) Tablets, First-in-Class Oral HIV-1 Integrase Inhibitor
- Vidiom Systems, Inc. Releases Version 1.0 of VISION Workbench OCAP Application Development Software
- Avantogen and Hawaii Biotech Combine Vaccine Businesses; World-Class Vaccine Developer is Created to Accelerate Pandemic Influenza, West Nile and Dengue Fever Vaccine Programs
- Trivantis' 2006 Release of Lectora Authoring Software Takes eLearning Development to the Next Level
- MIPI Alliance Releases Two Standards To Ease Camera Phone Development; Mobile Industry Collaborates on CSI-2 and D-PHY Specifications for Serial Camera Interface
- CHA Releases Findings of Inaugural Survey of Drug Development Activities in Emerging Regions By Western Biopharmaceutical Companies
- Xbox 360 Release Delayed, Price Announced
User Comments (0)
RSS Feeds